Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells

BACKGROUND: Current chemotherapies for Burkitt lymphoma (BL) have dramatically improved its clinical outcome. However, chemoresistance can lead to chemotherapy failure and very poor prognosis; thus, novel strategies are urgently required for patients with drug-resistant BL. To investigate the mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabata, Mitsuki, Tsubaki, Masanobu, Takeda, Tomoya, Tateishi, Keisuke, Tsurushima, Katsumasa, Imano, Motohiro, Satou, Takao, Ishizaka, Toshihiko, Nishida, Shozo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076888/
https://www.ncbi.nlm.nih.gov/pubmed/32171300
http://dx.doi.org/10.1186/s12906-020-2879-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076888/
https://www.ncbi.nlm.nih.gov/pubmed/32171300
http://dx.doi.org/10.1186/s12906-020-2879-8

Ejemplares similares